31 studies found for:    Icotinib OR BPI-2009H
Show Display Options
Rank Status Study
1 Active, not recruiting Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Conditions: EGFR Positive Non-small Cell Lung Cancer;   Adenocarcinoma
Interventions: Drug: Sequential Icotinib Plus Chemotherapy;   Drug: Icotinib
2 Recruiting Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Chemotherapy;   Drug: Icotinib+chemotherapy
3 Recruiting Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease
Condition: NSCLC
Interventions: Drug: Icotinib of routine dose;   Drug: Icotinib of high dose
4 Active, not recruiting Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to Icotinib
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Icotinib;   Drug: Arsenic trioxide
5 Active, not recruiting High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Routine dose icotinib;   Drug: Higher dose icotinib
6 Recruiting Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
Condition: Non-small-cell Lung Cancer
Interventions: Drug: 1-year treatment with icotinib;   Drug: 2-year treatment with icotinib
7 Not yet recruiting Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
Condition: NSCLC
Intervention: Drug: Icotinib
8 Recruiting Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Icotinib;   Radiation: intensity-modulated radiotherapy;   Drug: Paclitaxel and Cisplatin;   Other: Quality of life;   Genetic: Epidermal growth factor receptor status
9 Completed Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
Conditions: Non-small Cell Lung Cancer;   Brain Metastases
Interventions: Drug: icotinib;   Radiation: Whole brain radiotherapy
10 Not yet recruiting Icotinib Hydrochloride in Treating Patients With Advanced Cancers
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: icotinib hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
11 Recruiting Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Icotinib of routine dose;   Drug: Icotinib of high dose
12 Active, not recruiting Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
Condition: Non-small-cell Lung Cancer
Interventions: Drug: Icotinib;   Drug: Chemotherapy
13 Recruiting Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
Conditions: Lung Cancer;   Metastatic Cancer
Intervention: Drug: Icotinib
14 Not yet recruiting Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation
Condition: Lung Cancer
Interventions: Drug: 6-month Icotinib;   Drug: 12-month icotinib
15 Active, not recruiting Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: icotinib;   Drug: Gemcitabine
16 Recruiting Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy
Condition: Esophageal Squamous Cell Carcinoma
Intervention: Drug: Icotinib Hydrochloride
17 Active, not recruiting Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA (N0-1) Adenocarcinoma With EGFR Mutation
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Icotinib
18 Recruiting First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Icotinib
19 Active, not recruiting Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Mutation
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Carcinoma
Intervention: Drug: Icotinib
20 Active, not recruiting Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Icotinib

Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results
Indicates status has not been verified in more than two years